STOCKBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Updated 2026-06-14
Here’s whether Moderna, Inc. Common Stock (MRNA) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Neutral.
🔵
Neutral
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); RSI 58 — healthy momentum range; strong 1-year return of +82.5%. Concerns: 50-day MA is falling (-1.25% over 10 days); 3-month momentum negative (-6.4%); declining volume on rally — weak conviction (0.79x 30d avg). Currently 16.2% off its 52-week high. Score: +2/7.
MRNA is in a confirmed uptrend, trading above both its 50-day ($49.54) and 200-day ($38.54) moving averages. An RSI of 58.1 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +82.5% compares to +22.9% for SPY (beat the market by 59.6%).
$10,000 invested 1 year ago→ $18,249 today
vs. S&P 500 (SPY) — same period beat market by 59.6%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✓Above 200-day MA ($38.54)
✓Above 50-day MA ($49.54)
✓RSI(14) neutral zone (30–70) — currently 58.1
✓Positive return (+82.5%)
!Within 10% of period high (−16.2%)
Period Range $49.91
$22.28$59.55
RSI (14) 58.1
0 · OversoldOverbought · 100
Key Metrics
Price$49.91
Period Return+82.5%
Period High$59.55
Period Low$22.28
Drawdown−16.2%
MA-50$49.54
MA-200$38.54
RSI (14)58.1
Avg Volume (30d)7.2M
vs. SPYbeat by 59.6%
Return Rank#238 of 1246
Trend Signals
Price is above the 200-day moving average ($38.54)